Dergiler / Türk Patoloji Dergisi / 2020 / Cilt: 36 - Sayı: 2

Long-Term Effects of Tenofovir on Liver Histopathology in Patients with Chronic Viral Hepatitis B Infection

Sayfa
154–158
Yayın Tarihi
2022-11-05
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Improvement of liver necroinflammation was detected, but no significant change observed in fibrosis.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: The aim of this study to evaluate histopathological improvement and virological, serological and biochemical response rates inpatients with chronic hepatitis B (CHB) who were treated with tenofovir disoproxil fumarate (TDF).Material and Method: A total of 91 nucleosid(t)e-naive CHB patients who received TDF were evaluated.
📊
Temel Bulgular & Veri:Virological, serological and biochemicaltest results were assessed at baseline and every 12 weeks.
💡
Sonuç & Katkı:Improvement of liver necroinflammation was detected, but no significant change observed in fibrosis.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: The aim of this study to evaluate histopathological improvement and virological, serological and biochemical response rates inpatients with chronic hepatitis B (CHB) who were treated with tenofovir disoproxil fumarate (TDF).Material and Method: A total of 91 nucleosid(t)e-naive CHB patients who received TDF were evaluated. Virological, serological and biochemicaltest results were assessed at baseline and every 12 weeks. Liver biopsy specimens were assessed according to the modified Ishak scoring.Results: The study was conducted on 52 patients. The mean age was 40±10 years and 40.4% were female. The mean follow-up period was 33±11months. HBsAg seroclearance occurred in none of the patients. The serum level of HBV-DNA became undetectable in 94.2% of the patients.Mean histological activity index at baseline and on-treatment were 8.2±2.3 and 6.2±2.0 and the mean fibrosis scores were 2.65±1.3 and 2.33±1.1,respectively.Conclusion: We determined that TDF therapy provided remarkably good HBV DNA suppression and biochemical response rates, but lowseroconversion. Improvement of liver necroinflammation was detected, but no significant change observed in fibrosis.

🔖

Bu Makaleye Atıf Yap

TATAR, B., GÜL, S., KÖSE, Ş., PALA, E. (2022). Long-Term Effects of Tenofovir on Liver Histopathology in Patients with Chronic Viral Hepatitis B Infection. Türk Patoloji Dergisi, Cilt: 36 - Sayı: 2, 154–158. https://ajindex.com/articles/640412

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (8)

  1. Stasi C, Silvestri C, Voller F, Cipriani F. The epidemiological changes of HCV and HBV infections in the era of new antiviral therapies and the anti-HBV vaccine. J Infect Public Health. 2016;9:389-95
  2. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095-128
  3. Woo G, Tomlinson G, Nishikawa Y, Kowgier M, Sherman M, Wong DK, Pham B, Ungar WJ, Einarson TR, Heathcote EJ, Krahn M. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: A systematic review and Bayesian metaanalyses. Gastroenterology. 2010;139:1218-29
  4. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F. Tenofovir disoproxil fumarate versus adefovirdipivoxil for chronic hepatitis B. N Engl J Med. 2008;359:2442-55. 5. van Bömmel F, Wünsche T, Schürmann D, Berg T. Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. Hepatology. 2002;36:507-8
  5. Snow-Lampart A, Chappell B, Curtis M, Zhu Y, Myrick F, Schawalder J, Kitrinos K, Svarovskaia ES, Miller MD, Sorbel J, Heathcote J, Marcellin P, Borroto-Esoda K. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology. 2011;53:763-73
  6. Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Gurel S, Snow-Lampart A, Borroto-Esoda K, Mondou E, Anderson J, Sorbel J, Rousseau F. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology. 2011;140:132-43
  7. Lampertico P, Soffredini R, Viganò M, Yurdaydin C, Idilman R, Papatheodoridis G, Margariti K, Buti M, Esteban R, Zaltron S, Vavassori A, Carosi G, Minola E, Vinci M, et al. 2 year effectiveness and safety of tenofovir in 302 NUC-naïve patients with chronic hepatitis B: A multicenter European study in clinical practice. Hepatology. 2011;54(Suppl 1): Abstract 1433
  8. Carey I, Nguyen D